Heidelberg Pharma AG Presents Proprietary ATAC Technology Platform at Two Scientific Conferences
DGAP-News: Heidelberg Pharma AG / Key word(s): Conference
Heidelberg Pharma Presents Proprietary ATAC Technology Platform at Two Scientific Conferences
Ladenburg, Germany, 11 June 2019 - Heidelberg Pharma AG (FWB: WL6) today announced that they will present their proprietary technology for Antibody Targeted Amanitin Conjugates as potential therapeutic modality for cancer therapy at two upcoming scientific conferences.
2nd World ADC Asia Conference
Dr. George Badescu, Vice President Scientific Affairs, will present on Wednesday, 12 June 2019 at 14:30 CST.
Information on the conference: https://worldadc-asia.com/
Next Generation Protein Therapeutics & Bioconjugates Summit
Dr. George Badescu, Vice President Scientific Affairs, will present on Tuesday, 18 June 2019 at 11:00 PDT.
Information on the conference: https://get.knect365.com/next-gen-protein/brochure/
About Heidelberg Pharma's proprietary ATAC technology
About Heidelberg Pharma
The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON(R) and REDECTANE(R). Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
11.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||Heidelberg Pharma AG|
|Schriesheimer Str. 101|
|Phone:||+49 (0)89 41 31 38 - 0|
|Fax:||+49 (0)89 41 31 38 - 99|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||822219|
|End of News||DGAP News Service|